These results provide new insights into the changes in gene expression upon activation of the HER2/HER3 oncogenic unit and point to IL8 and its receptor CXCR1 as possible therapeutic targets for the treatment of invasive HER2/HER3/IL8-positive breast cancers. The gene discussed is CXCL8; the disease is breast cancer.